Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 1/20 | 0.56 |
| ▸ | GRM6 | O15303 | 1/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.56 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.56 |
| ▸ | GSR | P00390 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 1/20 | 0.56 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.56 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.56 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.56 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.56 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6119573 | 1.00 | GRM8 (0.56) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL8505283 | 1.00 | GRM8 (0.56) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL3681082 | 0.93 | PTGS1 (0.50) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL3681089 | 0.93 | PTGS1 (0.50) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL30481166 | 0.93 | PTGS1 (0.50) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL22479710 | 0.88 | GRM8 (0.52) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL11957999 | 0.88 | GRM8 (0.52) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL2483655 | 0.88 | BLM (0.55) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL16203683 | 0.88 | PTGS1 (0.56) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL2483653 | 0.88 | BLM (0.55) | GRM8GRM6GRIN2DGRIN3BGSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 462 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724061-A2 | PRODRUGS FOR COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | Cytosite Biopharma Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4659591-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | House Foods Group Inc. (JP) | 2025-12-10 | — | — | EP | claimed |
| EP-4659592-A1 | FLAVOR ENHANCING COMPOSITION, MANUFACTURING METHOD THEREFOR, AND METHOD FOR ENHANCING FLAVOR OF FOOD PRODUCT | House Foods Corporation (JP) | 2025-12-10 | — | — | EP | claimed |
| EP-4025192-B1 | PROCESS FOR PRODUCING A TABLET COMPRISING GLP-1 PEPTIDES | NOVO NORDISK AS (DK) | 2025-12-03 | — | — | EP | claimed |
| EP-4652183-A1 | PEPTIDE-DRUG CONJUGATES FOR TARGETED THERAPY OF RENAL DISEASES | Shanghai MicuRx Pharmaceutical Co., Ltd. (CN) | 2025-11-26 | — | — | EP | claimed |
| EP-4566632-A1 | MSLN ANTIBODY-DRUG CONJUGATE | Nona Biosciences (Suzhou) Co., Ltd. (CN) | 2025-06-11 | — | — | EP | claimed |
| US-20250154226-A1 | LONG-ACTING GLP-1/GLP-2 DUAL AGONIST COMPOUND | Chengdu AODA Biotechnology Co., Ltd (CN) | 2025-05-15 | — | — | US | claimed |
| US-20250135018-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | SEAGEN INC (US) | 2025-05-01 | — | — | US | claimed |
| CN-119907693-A | MSLN antibody drug conjugates | 诺纳生物（苏州）有限公司 | 2025-04-29 | — | — | CN | claimed |
| US-20250108119-A1 | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF | IMMUNEXT INC. | 2025-04-03 | — | — | US | claimed |
| US-20220193069-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | SEAGEN INC (US) | 2022-06-23 | — | — | US | claimed |
| EP-3538543-B1 | PROTRANSDUZIN-S - AN ENHANCER OF GENE TRANSFER | PHARIS BIOTEC GMBH (DE) | 2022-06-08 | — | — | EP | claimed |
| US-11332497-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2022-05-17 | — | — | US | claimed |
| WO-2022078524-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-04-21 | — | — | WO | claimed |
| CN-114340655-A | Method for producing tablets comprising GLP-1 peptides | 诺和诺德股份有限公司 | 2022-04-12 | — | — | CN | claimed |
| US-20220062184-A1 | Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release Coating | NOVO NORDISK AS (DK) | 2022-03-03 | — | — | US | claimed |
| US-20220031810-A1 | FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES | ZEALAND PHARMA A/S (DK) | 2022-02-03 | — | — | US | claimed |
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | claimed |
| US-6239111-B1 | DRUG FOR TREATING BRAIN DISEASES, ENABLES PREVENTION OR TREATMENT OF DEMENTIA AND SIMILAR DISEASES CAUSED BY DEGENERATION OR SLOUGHING OF NEURONS, AN ALLY SULFIDE, SULFOXIDE OR SULFONE | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-29 | — | — | US | claimed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250135018-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | VIP, DCLRE1A, UACA | GRM8 4211/4885GRM6 4636/4885GRIN2D 4845/4885 |
| US-20220062184-A1 | Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release Coating | GLP1R, GIPR, IAPP | GRM8 1512/4885GRM6 1534/4885GRIN2D 3728/4885 |
| US-20220193069-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | VIP, DCLRE1A, UACA | GRM8 4211/4885GRM6 4636/4885GRIN2D 4845/4885 |
| US-20250108119-A1 | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF | FCGR2A, FCER2, FCGR1A | GRM8 446/4885GRM6 868/4885GRIN2D 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.